ProCE Banner Activity

My Take on New Advances in CLL From ASCO 2019

Clinical Thought
Are you aware of some of the latest clinical data in CLL? In this commentary I will discuss 3 key studies on venetoclax acalabrutinib and lisocabtagene maraleucel in CLL that were presented at ASCO 2019.

Released: June 27, 2019

Expiration: June 25, 2020

No longer available for credit.

Share

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Pharmacyclics AbbVie

Verastem Oncology

Partners

CLL Society

ProCE Banner